GenMont Biotech (TPE:3164) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:3164 GenMont Biotech Inc TPE:3164
81 GF Score
Price NT$15.85
GF Value NT$21.07
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is GenMont Biotech Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GenMont Biotech  (TPE:3164) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


GenMont Biotech Cyclically Adjusted PS Ratio Related Terms


GenMont Biotech Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for GenMont Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenMont Biotech Cyclically Adjusted PS Ratio Chart

GenMont Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.18 3.89 4.12 3.69 3.49

GenMont Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 3.47 3.38 3.34 2.95

TPE:3164 vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, GenMont Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMont Biotech Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GenMont Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GenMont Biotech's Cyclically Adjusted PS Ratio falls into.


TPE:3164
81GF Score
GenMont Biotech Inc TPE:3164
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenMont Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

GenMont Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, GenMont Biotech's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.2/333.9520*333.9520
=1.200

Current CPI (Jun. 2026) = 333.9520.

GenMont Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.645 241.428 2.275
201612 1.355 241.432 1.874
201703 1.484 243.801 2.033
201706 1.135 244.955 1.547
201709 1.809 246.819 2.448
201712 0.821 246.524 1.112
201803 1.080 249.554 1.445
201806 1.092 251.989 1.447
201809 1.326 252.439 1.754
201812 1.064 251.233 1.414
201903 1.019 254.202 1.339
201906 0.968 256.143 1.262
201909 0.935 256.759 1.216
201912 0.961 256.974 1.249
202003 0.902 258.115 1.167
202006 0.887 257.797 1.149
202009 0.904 260.280 1.160
202012 1.006 260.474 1.290
202103 1.199 264.877 1.512
202106 1.149 271.696 1.412
202109 1.216 274.310 1.480
202112 1.375 278.802 1.647
202203 1.049 287.504 1.218
202206 1.106 296.311 1.246
202209 0.880 296.808 0.990
202212 1.222 296.797 1.375
202303 0.920 301.836 1.018
202306 1.017 305.109 1.113
202309 0.882 307.789 0.957
202312 0.857 306.746 0.933
202403 1.343 312.332 1.436
202406 1.087 314.175 1.155
202409 0.967 315.301 1.024
202412 1.040 315.605 1.100
202503 1.147 319.799 1.198
202506 1.297 322.561 1.343
202509 1.032 324.800 1.061
202512 1.164 324.054 1.200
202603 1.034 330.213 1.046
202606 1.200 333.952 1.200

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is GenMont Biotech (TPE:3164) Overvalued in 2026?

Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued. The current stock price of NT$15.85 is trading 24.8% below its estimated GF Value™ of NT$21.07. GuruFocus considers GenMont Biotech to be Modestly Undervalued.

Key valuation signals for TPE:3164:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: NT$21.07 vs. price of NT$15.85 (24.8% below fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GenMont Biotech Business Description

Address No. 8 Nanke 7th Road, Tainan Science and Technology Park, Shanhua District, Tainan, TWN, 741014
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
81GF Score

Get the complete analysis for TPE:3164

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.85
Price
NT$21.07
GF Value